Endoron Medical

Executive Summary

Endoron Medical is an Israeli medtech startup developing innovative transcatheter endovascular anchoring devices for aortic interventions. Its lead technologies, Aortodock and Aortoseal, address critical limitations of current TAVR and EVAR procedures by providing calcium-independent fixation, enabling treatment of aortic regurgitation and complex aneurysm anatomies. This approach could significantly expand the patient population eligible for minimally invasive aortic repair and improve procedural safety. Founded in 2020 and headquartered in Yokne'am Illit, Israel, Endoron is currently in the preclinical stage and has raised approximately $2.7M to date. The company is leveraging its proprietary anchoring platform to differentiate from established competitors. Upcoming milestones include completing additional preclinical studies, securing Series A financing, and initiating regulatory discussions. Success in these areas could position Endoron for first-in-human trials and eventual commercialization.

Upcoming Catalysts (preview)

• Q4 2026Completion of key preclinical study results60% success
• Q1 2027Series A financing round50% success
• TBDFirst-in-human clinical trial initiation30% success